Table 4.
Comparison of the findings of the current study with those of previous studies associated with advanced mucinous ovarian carcinoma
| Author | Number of women with MOC | Stage of disease | Extent of residual disease | Median PFS (months) | Media OS (months) |
|---|---|---|---|---|---|
| Hess, 2004 [18] | 27 | III, IV | optimal or suboptimal | 5.7 | 12.0 |
| Pectasides, 2005 [27] | 47 | III, IV | optimal or suboptimal | 11.8 | 33.2 |
| Winter, 2007 [19] | 34 | III | optimal or suboptimal | 10.5 | 14.8 |
| Bamias, 2010 [8] | 24 | III, IV | optimal or suboptimal | NR | 15.4 |
| Mackay, 2010 [20] | 264 | III, IV | optimal or suboptimal | 7.6 | 14.6 |
| Bamias, 2012 [21] | 21 | III, IV | optimal or suboptimal | NR | 15.0 |
| Karabuk, 2013 [14] | 50 | III, IV | optimal or suboptimal | 7.0 | 35.0 |
| Current study | 81 | III | maximal or optimal | 18.0 | 45.0 |
Abbreviations: MOC mucinous ovarian carcinoma, PFS progression-free survival, OS overall survival, NR not reported